Alloprenanolone: Neurogenic Property and Therapeutic Potential in AD Treatment
CSEF · 2007 Pharmacology/ Toxicology
Overview
Objectives/Goals Objectives: We investigated whether APa promotes generation of new neurons in vivo by peripheral administration in transgenic 3xTgAD and non-Tg mouse AD models; and whether GABAA receptor complex (GBRC) is involved in the neurogenic activity of APa in hNPCs. Methods/Materials Methods: The newly-formed cells were labeled by BrdU and the samples were evaluated by stereological analyses in the subgranular zone (SGZ) of dentate gyrus. Neurogenic abilities of APa and its analogs in hNPCS are determined by BrdU incorporation. Expression of GBRC subunits in hNPCs were determined by RT-PCR and immunocytochemistry. Results Results: Stereological analyses demonstrated that the basal level of BrdU labeled cells in the dentate gyrus of 3xTgAD mouse was lower than that of non-Tg mice. APa induced a significant increase of newly-formed cells in SGZ of both non-Tg and 3xTgAD mouse. APa restored SGZ proliferation to that of control non-Tg mice. Immunochemical labeling demonstrated the expression of GABAergic system in hNPCs and RT-PCR detection demonstrated the expression of alpha 1/5, beta 2 and delta subunits. Steroid specificity assay demonstrated the involvement of GBRC and structural specificity. Conclusions/Discussion Conclusions: In vivo, APa rescues the neurogenic impairment of 3xTgAD mouse and enhances the proliferative capacity of both the non-Tg and transgenic phenotypes. Results suggest that APa may be an effective neurogenic therapeutic to promote neurogenesis prior to the onset of AD pathology.
Summary statement
The effects of neurosteroid Allopregnanolone has positive results with cell proliferation in brain.
Help received
Mentor: Lifei Liu, PI: Dr. Roberta Diaz Brinton, USC School of Pharmacy
Competition history
- CSEF 2007
Resources
Related projects
CSEF · 2015
Allopregnanolone Site of Action for Promoting Regeneration of Human Neural Stem Cells: Uncovering the Paths
CSEF · 2003
Neuroprotective Efficacy of Therapeutic Progestins: Implications for Alzheimer's Disease
ISEF · 2026
A Multi-Target Chronopharmacotherapy for the Inhibition and Clearance of Toxic Proteins in Alzheimer's Disease
ISEF · 2015
High Throughput AD Drug Screening of Alpha-Secretase Activity Modulators as a Novel Model for Alzheimer's Disease
CWSF · 2026
NeuroRegen: In-Silico Design of Dual-Action Intranasal Nanoparticle Therapy for Alzheimer’s Disease
ISEF · 2014
Nicotine and Genistein as Novel Therapeutic Agents for Alzheimer's Disease
AJAS · 2019
A Novel Bifunctional Conjugate to Treat Neurodegenerative Disorders
ISEF · 2015
Treating Alzheimer's Disease: New Proposal for Grayanotoxin Ligand Binding to the Carbonic Anhydrase I Receptor
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: California Science & Engineering Fair public projects